Method of prognosis and follow up of primary liver cancer

A technology for primary liver cancer and liver cancer, applied in the new non-invasive quantitative testing field, can solve the problems of difficult detection of primary liver cancer and low incidence of cancer

Pending Publication Date: 2020-06-12
BIOPREDICTIVE +1
View PDF16 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] However, given the relatively low incidence of this cancer in this group (approximately 1-2% of patien

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of prognosis and follow up of primary liver cancer
  • Method of prognosis and follow up of primary liver cancer
  • Method of prognosis and follow up of primary liver cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0242] Embodiment 1. Method

[0243] Functions were obtained in a group of 9925 patients with chronic liver disease (termed the pre-inclusion population), all patients were subjected to FibroTest measurements (Fibrotest as disclosed in WO 2002 / 016949). Since the Fibrotest formula is 4.467×Log(α2 macroglobulin (g / l))-1.357×Log(haptoglobin (g / l))+1.017×Log(GGT(IU / l))+0.0281×age (years )+1.737×Log(bilirubin (μmol / l))-1.184×ApoA1(g / l)+0.301×gender (female=0, male=1)-5.540, which ensures that the measured α2 macroglobulin, Haptoglobin, GGT, age (when Fibrotest was performed), bilirubin, ApoA1 levels, and sex were all available. Furthermore, patients were pre-enrolled only if they had no previous liver transplant and had no history of PLC.

[0244] Primary liver cancer was defined as hepatocellular carcinoma (HCC) or cholangiocarcinoma (CC) according to biopsy, or if no biopsy was available, according to Barcelona criteria or death certificate.

[0245]In the constitutive popul...

Embodiment 2

[0257] Example 2. Evaluation of functions

[0258] Determining the diagnostic capabilities of a function

[0259] In P0, AUROC = 0.915 (0.889-0.936) for the HR-Test, a combination of three proteins, one liver function test, age and sex, as shown in fl-a.

[0260] In P1, the HR test retrieved a significant AUROC = 0.828 (0.803-0.850), while in the paired cases of P2: = 0.812 (CI 0.772-0.846).

[0261] Other data as shown – Determination of functional prognostic ability

[0262] from figure 1 As can be seen in , a blood test (HR1V4) using the same markers is more sensitive and specific for detecting the presence of primary liver cancer (simultaneous liver cancer) than the Fibrotest test (which actually uses fewer biochemical markers), with a higher The AUROC proves this.

[0263] figure 2 A blood test using the fibrosis markers used in Fibrotest and AFP (a liver cancer marker) was shown to be more sensitive and specific for the presence of primary liver cancer (synch...

Embodiment 3

[0269] Example 3. Development of Cox functions

[0270] Specimens prospectively collected by an ongoing group were retrospectively analyzed. To design an early sensitive high-risk test (HR1c-test), hepatoprotective proteins (apolipoprotein A1, haptoglobin) were compared with known risk factors (sex, age, γ-glutamyl transpeptidase), and liver fibrosis marker (α2-macroglobulin) combined in the Cow model. These components were then combined with alpha-fetoprotein, a direct marker of liver cancer, in order to increase specificity (HR2c-test). The primary endpoint was the prediction of HCC by HR1 at 10 years, with HR2 having higher performance than alpha-fetoprotein at 5 years.

[0271] result. A total of 9,892 patients were included, 85.9% without cirrhosis, followed for a median of 5.9 years [IQR; 4.3-9.4]. 221 patients developed liver cancer. The time-dependent area under the ROC curve (AUROC-T) for HR1 to predict cancer was 0.874 (95% confidence interval [CI], 0.838 to 0...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to new methods for assessing the risk of a patient, in particular with chronic liver disease, to develop primary liver cancer over time, using functions combining blood biochemical markers.

Description

technical field [0001] The present invention relates to a new non-invasive quantitative test which, inter alia, makes it possible to detect patients prone to developing liver cancer. Background technique [0002] Primary liver cancer is cancer of the liver cells, when normal cells in the liver become abnormal, then destroy adjacent normal tissue, and spread to other areas of the liver and organs outside the liver. [0003] Most people who develop liver cancer (liver cancer) develop it in the context of chronic liver disease. In fact, the main causes of liver cancer are hepatitis B, hepatitis C, and cirrhosis from nonalcoholic (NAFLD) or alcoholic (ALD) fatty liver disease. Indeed, advanced fibrosis (F2, F3 or F4 according to METAVIR classification) is present in more than 90% of primary liver cancer cases. [0004] The most common types are hepatocellular carcinoma (HCC) (80% of cases) and cholangiocarcinoma. Less common types include mucinous cystic neoplasms and intradu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/574G16H50/30G16H10/00
CPCG01N33/57438G01N2333/775G01N2333/81G01N2333/9108G01N2800/50G16H50/30G16H10/40A61K45/06G06F17/18
Inventor T·波纳德
Owner BIOPREDICTIVE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap